CASSIOPEA SPA
- Country
- 🇮🇹Italy
- Ownership
- Public, Subsidiary
- Established
- 2013-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.cassiopea.com
Clinical Trials
12
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (12 trials with phase data)• Click on a phase to view related trials
A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss (SCALP2)
- Conditions
- Alopecia, Androgenetic
- Interventions
- Drug: Vehicle solution
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- Cassiopea SpA
- Target Recruit Count
- 726
- Registration Number
- NCT05914805
- Locations
- 🇺🇸
Investigate MD, Scottsdale, Arizona, United States
🇺🇸Physician's Institute of Cosmetic and Reconstructive Surgery, Hollywood, Florida, United States
🇺🇸DelRicht Research, Thompson's Station, Tennessee, United States
A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss
- Conditions
- Alopecia, Androgenetic
- Interventions
- Drug: Vehicle solution
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Cassiopea SpA
- Target Recruit Count
- 726
- Registration Number
- NCT05910450
- Locations
- 🇺🇸
The Petrus Center for Aesthetic Surgery and Hair Transplantation, North Little Rock, Arkansas, United States
🇺🇸Therapeutics Clinical Research, San Diego, California, United States
🇺🇸Mayo Clinic, Department of Dermatology, Jacksonville, Florida, United States
A Study to Investigate the Effects of Cortexolone 17α-propionate (and Its Metabolites) on Healthy Volunteers' Heart
- Conditions
- Healthy Volunteers
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-09-11
- Last Posted Date
- 2019-02-04
- Lead Sponsor
- Cassiopea SpA
- Target Recruit Count
- 32
- Registration Number
- NCT03665194
- Locations
- 🇬🇧
Richmond Pharmacology Ltd, London, United Kingdom
An Evaluation of the Adrenal Suppression Potential and PK of CB-03-01 Cream in Pediatric Patients With Acne Vulgaris
- First Posted Date
- 2016-03-28
- Last Posted Date
- 2020-11-20
- Lead Sponsor
- Cassiopea SpA
- Target Recruit Count
- 27
- Registration Number
- NCT02720627
- Locations
- 🇺🇸
Site 103, Fort Smith, Arkansas, United States
🇺🇸Site 101, San Diego, California, United States
🇺🇸Site 102, Houston, Texas, United States
An Open-Label, Long-Term Extension Study to Evaluate the Safety of CB-03-01 Cream, 1% in Participants With Acne Vulgaris
- Conditions
- Acne Vulgaris
- Interventions
- Drug: CB-03-01 cream, 1%
- First Posted Date
- 2016-02-15
- Last Posted Date
- 2020-11-17
- Lead Sponsor
- Cassiopea SpA
- Target Recruit Count
- 609
- Registration Number
- NCT02682264
- Locations
- 🇺🇸
Johnson Dermatology, Fort Smith, Arkansas, United States
🇺🇸Gary M. Petrus, MD PA, Little Rock, Arkansas, United States
🇺🇸Center for Dermatology and Laser Surgery, Sacramento, California, United States
- Prev
- 1
- 2
- Next